Search results for "1H"

showing 10 items of 1291 documents

CCDC 2060888: Experimental Crystal Structure Determination

2021

Related Article: Lucija Ptiček, Lucija Hok, Petra Grbčić, Filip Topić, Mario Cetina, Kari Rissanen, Sandra Kraljević Pavelić, Robert Vianello, Livio Racané|2021|Org.Biomol.Chem.|19|2784|doi:10.1039/D1OB00235J

hydrogen bis(2-(3-amino-4-oxyphenyl)-45-dihydro-1H-imidazol-3-ium) chloride tetrahydrateSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

Mechanisms of arachidonic acid induced glial swelling

2000

Accumulation of arachidonic acid (AA) in the brain during ischaemia may contribute to development of brain oedema. In this study we investigated the effect of selected drugs on AA-induced cytotoxic brain oedema in C6 glioma cells. Suspended C6 glioma cells were preincubated with drugs and AA (0.1 mM) was added. When no drug was administered cell volume increased immediately after the addition of AA with a maximum cell swelling of 13.1+/-1.9% at 15 min (mean +/- S.E. M.). Preincubation of cells with BW 755C, a dual inhibitor of cyclo- and lipoxygenases, showed no reduction in cell swelling from AA, whereas superoxide dismutase, amiloride and the protein kinase inhibitor H-9370 led to a signi…

medicine.drug_classModels Neurological45-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amineBrain EdemaPharmacologyAmilorideSuperoxide dismutaseCellular and Molecular Neurosciencechemistry.chemical_compoundTumor Cells CulturedmedicineAnimalsCytotoxic T cellEnzyme InhibitorsOuabainMolecular BiologyCell SizeArachidonic AcidbiologySuperoxide DismutaseGliomaProtein kinase inhibitorIn vitroAmiloridemedicine.anatomical_structurechemistryCell cultureImmunologybiology.proteinNeurogliaArachidonic acidNeurogliamedicine.drugMolecular Brain Research
researchProduct

Clearance and metabolism of arachidonic acid by C6 glioma cells and astrocytes.

1995

Effects of increased levels of arachidonic acid (AA) were analyzed in vitro by employment of C6 glioma cells and astrocytes from primary culture. The cells were suspended in a physiological medium added with arachidonic acid (AA) in a concentration range from 0.01 to 0.5 mM. The concentration profiles of the fatty acid and AA-metabolites were subsequently followed for 90 min. AA was measured by gas chromatography, whereas the AA-metabolites PGF2 alpha and LTB4 by radioimmunoassay (RIA). Following administration of AA at 0.05 or 0.1 mM the medium was completely cleared from the fatty acid within 10 to 15 min. However, when 0.5 mM were added, AA concentrations of 0.36 +/- 0.055 mM were found …

medicine.medical_specialty45-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amineBiologyDinoprostBiochemistryLeukotriene B4Cellular and Molecular NeuroscienceLipoxygenasechemistry.chemical_compoundInternal medicinemedicineTumor Cells CulturedCyclooxygenase InhibitorsLipoxygenase Inhibitorschemistry.chemical_classificationArachidonic AcidFatty acidRadioimmunoassayGeneral MedicineMetabolismGliomaCulture MediaKineticsEndocrinologymedicine.anatomical_structurechemistryCell cultureAstrocytesbiology.proteinNeurogliaArachidonic acidAstrocyteNeurochemical research
researchProduct

Direct-acting antivirals ombitasvir/paritaprevir/rotonavir+dasabuvir with or without ribavirin in hepatitis C virus (HCV) genotype 1-infected treatme…

2018

Background: The current international multicentre open-label, uncontrolled, real-world retrospective study aimed at evaluating the effectiveness and safety of ombitasvir / paritaprevir / ritonavir + dasabuvir ± ribavirin (3D therapy) in treatment-naive and treatment-experienced hepatitis C virus (HCV) genotype 1-infected (GT1) patients. Methods: Adult patients with chronic HCV GT1 infection, scheduled for 3D therapy according to therapeutic guidelines, were eligible. Demographic and clinical data were collected retrospectively by reviewing individuals health records. The primary effectiveness endpoint was the sustained virological response at 12 weeks following the end of treatment (SVR12).…

medicine.medical_specialtyDasabuvirCirrhosisHepatologymedicine.diagnostic_testbusiness.industryRibavirinmedicine.diseaseOmbitasvir03 medical and health scienceschemistry.chemical_compoundRegimen0302 clinical medicineInfectious DiseaseschemistryParitaprevirInternal medicinemedicine030211 gastroenterology & hepatologyRitonavir030212 general & internal medicineChronic hepatitis C ; genotype-1HCV ; ombitasvir ; paritaprevir ; dasabuvir ; cirrhosis ; liver transplant ; 3D therapyLiver function testsbusinessmedicine.drug
researchProduct

Response to dopamine agonists of the rat isolated uterus.

1993

1. Quinpirole did not produce any effect in isolated uterus from oestrogenized rats even when it is contracted by KCl (37 mM). 2. Fenoldopam produced a relaxant effect on rat isolated uterus contracted by KCl which was not significantly modified by SCH 23390. 3. Reserpine decreased the effect of the lowest doses of fenoldopam. In reserpinized rats, propranolol (10(-9), 10(-8), 10(-7) M) antagonized the effect of the lowest doses of fenoldopam and neither SCH 23390, sulpiride nor ranitidine modified the effect of fenoldopam. 4. The results confirm our previous finding that DA1-receptors are not functional in our preparation. The effect of fenoldopam was partially due to a catecholamine-relea…

medicine.medical_specialtySerotoninQuinpiroleReserpineFenoldopamDopamine AgentsUterusPropranololPharmacologyFenoldopamIn Vitro TechniquesDopamine agonistchemistry.chemical_compoundUterine ContractionQuinpiroleCatecholaminesInternal medicineReceptors Adrenergic betamedicineAnimalsErgolinesRats WistarPharmacologySCH-23390ChemistryReserpineAcetylcholineRatsEndocrinologymedicine.anatomical_structureFemale2345-Tetrahydro-78-dihydroxy-1-phenyl-1H-3-benzazepineSulpiridemedicine.drugGeneral pharmacology
researchProduct

CCDC 2149627: Experimental Crystal Structure Determination

2022

Related Article: Adrian Laviós, Amparo Sanz-Marco, Carlos Vila, M. Carmen Muñoz, José R. Pedro, Gonzalo Blay|2022|Org.Lett.|24|2149|doi:10.1021/acs.orglett.2c00427

methyl (1R3S3aR8bR)-7-bromo-3-methoxy-3a-nitro-1-phenyl-233a8b-tetrahydro-1H-[1]benzofuro[23-c]pyrrole-1-carboxylateSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 985005: Experimental Crystal Structure Determination

2014

Related Article: Frank Bohland, Irina Erlin, Lukas Platte, Maike Schröder, Dieter Schollmeyer, Udo Nubbemeyer|2014|Eur.J.Org.Chem.|2014|6272|doi:10.1002/ejoc.201402720

methyl 1-benzyl-8-((t-butyl(dimethyl)silyl)oxy)-3-chloro-2-oxo-234789-hexahydro-1H-azonine-4-carboxylateSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 1444032: Experimental Crystal Structure Determination

2016

Related Article: Fares Ibrahim Amr, Carlos Vila, Gonzalo Blay, M. Carmen Muñoz and José R. Pedro|2016|Adv.Synth.Catal.|358|1583|doi:10.1002/adsc.201600036

t-butyl (1-benzyl-5-chloro-3-(34-dimethyl-5-oxo-1-phenyl-45-dihydro-1H-pyrazol-4-yl)-2-oxo-23-dihydro-1H-indol-3-yl)carbamateSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

CCDC 2092891: Experimental Crystal Structure Determination

2021

Related Article: Laura Carceller-Ferrer, Carlos Vila, Gonzalo Blay, M. Carmen Muñoz, José R. Pedro|2021|Org.Lett.|23|7391|doi:10.1021/acs.orglett.1c02571

t-butyl {1-(methoxymethyl)-3-[2-(3-methyl-5-oxo-1-phenyl-15-dihydro-4H-pyrazol-4-ylidene)propyl]-2-oxo-23-dihydro-1H-indol-3-yl}carbamateSpace GroupCrystallographyCrystal SystemCrystal StructureCell ParametersExperimental 3D Coordinates
researchProduct

Dokumenttityypin paperi- ja internetversion vertailu : genre-analyysi emokasvihinnastosta

2006

tapaustutkimussisällönhallintagenre-teoria5W1H-viitekehysmallidokumentointi
researchProduct